Scanogen has developed a groundbreaking technology known as Single MOLecule Tethering (SMOLT), which enables ultra-sensitive and rapid detection of nucleic acids and microorganisms in various body fluids. This amplification-free approach allows for direct detection of pathogens without the need for nucleic acid amplification, significantly reducing the time required for diagnostic results. The SMOLT platform utilizes a unique biosensor structure where micron-sized beads are tethered by DNA long probes. The detection process involves measuring the displacement of these beads, which generates a digital signal based on single-molecule counts, allowing for precise identification of target molecules.

The advantages of SMOLT technology are substantial, particularly in the context of sepsis diagnosis. Traditional blood culture methods can take several days, leading to delays in treatment for patients. In contrast, SMOLT can provide actionable results in under 90 minutes, enabling timely and appropriate medical intervention. Additionally, the technology supports the multiplexing of over ten targets in a single reaction, making it versatile for various diagnostic applications. With its cost-effective reagents and instrumentation, as well as safety from contamination and polymerase inhibition, SMOLT represents a significant advancement in molecular detection technologies.

United States

Scanogen is a molecular diagnostic company developing systems to read the biomolecular information of body fluids with the goal of improving health care. The Company has developed Single MOLecule Tethering (SMOLT), a proprietary technology for rapid and ultra-sensitive detection of biomolecules. The Company is using this technology to develop a simple-to-use and sample-to-answer diagnostic platform. Scanogen has received NIH grants totaling $9.5 million to develop its diagnostic assays and it is currently focused on two areas: Point-of-care diagnosis and bloodstream infection detection.

Scanogen

Company Details